Intellia reported additional positive Phase 3 results for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, extending the readout beyond the primary endpoint announced earlier in the year. The company said the therapy met multiple key secondary endpoints, including reduced monthly attack rates requiring on-demand treatment and improved AE-QoL outcomes. The update strengthens Intellia’s rationale for continuing rolling submission of a Biologics License Application begun in April, with the company expecting to complete the filing by year-end. Intellia also told investors that the clinical program replicated the pattern seen across earlier studies, including durable attack control and patients being off long-term prophylaxis. The data were presented at EAACI 2026 and published in The New England Journal of Medicine, giving the program high visibility for regulators and payers.